-
Company Insights
Innovation and Patenting activity of Shimao Services Holdings Ltd Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Shimao Services Holdings Ltd Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...
-
Company Insights
Innovation and Patenting activity of Shimao Group Holdings Ltd Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Shimao Group Holdings Ltd Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...
-
Product Insights
Pulmonary Embolism – Drugs In Development, 2023
Global Markets Direct’s, ‘Pulmonary Embolism - Drugs In Development, 2023’, provides an overview of the Pulmonary Embolism pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pulmonary Embolism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Thromboembolism – Drugs In Development, 2023
Global Markets Direct’s, ‘Thromboembolism - Drugs In Development, 2023’, provides an overview of the Thromboembolism pipeline landscape. The report provides comprehensive information on the therapeutics under development for Thromboembolism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Venous Thromboembolism – Drugs In Development, 2023
Global Markets Direct’s, ‘Venous Thromboembolism - Drugs In Development, 2023’, provides an overview of the Venous Thromboembolism pipeline landscape. The report provides comprehensive information on the therapeutics under development for Venous Thromboembolism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Thrombosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Thrombosis - Drugs In Development, 2023’, provides an overview of the Thrombosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Thrombosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Acute Ischemic Stroke – Drugs In Development, 2023
Global Markets Direct’s, ‘Acute Ischemic Stroke - Drugs In Development, 2023’, provides an overview of the Acute Ischemic Stroke pipeline landscape. The report provides comprehensive information on the therapeutics under development for Acute Ischemic Stroke, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tenecteplase in Pulmonary Embolism
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tenecteplase in Pulmonary Embolism report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tenecteplase in Pulmonary Embolism Drug Details: Tenecteplase (Tianlitong) is a recombinant tissue...
-
Product Insights
Ischemic Stroke – Drugs In Development, 2023
Global Markets Direct’s, ‘Ischemic Stroke - Drugs In Development, 2023’, provides an overview of the Ischemic Stroke pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ischemic Stroke, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Shimao Group – Fuzhou Shimao 108 Building – Fujian
Equip yourself with the essential tools needed to make informed and profitable decisions with our Shimao Group - Fuzhou Shimao 108 Building - Fujian report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into...